Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
320
Trial Sponsor
Clinical Trial Start Date
2010
0Primary Completion Date
2012
0Study Completion Date
2012
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Tolerability of a Single Dose of Intravenous ALN-TTR01 in Patients With TTR Amyloidosis0
Last Updated
May 24, 2012
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Single0
Masked Party
Participant0
Other attributes
Intervention Treatment
ALN-TTR010
Sterile Normal Saline (0.9% NaCl)0
Study summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR01 in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
